Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (2010) / Chapter Skim
Currently Skimming:
Appendix F: Speaker Biographies
Appendix F: Speaker Biographies
Pages 307-314
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 307... ...
Ballantyne, M.D., Atherosclerosis Laboratory; professor of medicine with a joint appointment in Pediatrics, Baylor College of Medicine; and codirector, Lipid Metabolism and Atherosclerosis Clinic, The Methodist Hospital, Houston, Tx. He received his Doctor of Medicine from Baylor College of Medicine, and his postgraduate train ing included an internal medicine residency at The University of Texas Southwestern Medical School, a cardiology fellowship at Baylor College of Medicine, and an American Heart Association (AHA)
|
From page 308... ...
, A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) , National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II (NEPTUNE II)
|
From page 309... ...
His primary research interest is risk assessment and management of acute and chronic coronary artery disease. His other research interests include electrocardiography as a means of assessing the coronary microcirculation after thrombolysis or percutaneous coronary intervention, and the use of novel biomarkers for prognostic assessment among patients with coronary artery disease.
|
From page 310... ...
One research stream, funded by the NCI, is to apply management principles to significantly reduce the time and steps required to open oncology clinical trials. This research has completed in-depth examinations of four NCIdesignated Comprehensive Cancer Centers, two major oncology cooperative groups, the NCI Cancer Therapy Evaluation Program, and the NCI Centralized Institutional Review Board.
|
From page 311... ...
and postgradu ate training in Comparative Toxicology at Cornell University. He is a past guest lecturer in Safety Risk Assessment and Risk Management at Northeastern University and Yale University, and is currently on the faculty of the Harvard–Massachusetts Institute of Technology Clinical Investigator Training Program, where he provides practical insight into safety assess
|
From page 312... ...
Her research has been supported by a Young Investigator Award from the American Society of Clinical Oncology. Her current and past research support includes the Timely Special Opportunity Award from the DanaFarber Cancer Institute, the NIH Loan Repayment Program, and the Clinical Research Feasibility Fund Award from BIDMC.
|
From page 313... ...
Later, he completed a medical internship at Rush University/ Presbyterian Medical Center in Chicago, followed by a neurology residency at University of Rochester. Following residency he moved to the National Institute of Neurological Disorders and Stroke, NIH, as a Senior Staff Fellow engaging in research on the development of neurotransmitter responses in the embryonic spi
|
From page 314... ...
at the FDA as a medical officer. His work initially focused on clinical trials of investigational biological products (proteins, monoclonal antibodies, cellular therapies, and gene transfer therapies)
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.